Related references
Note: Only part of the references are listed.Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
Bruno Sinn et al.
CLINICAL CANCER RESEARCH (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
Julia Foldi et al.
NPJ BREAST CANCER (2021)
The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy
Huimin Du et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prognostic value of immune checkpoint molecules in breast cancer
Jun Fang et al.
BIOSCIENCE REPORTS (2020)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
Nina D'Abreo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial
Peter John et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Hauke Stamm et al.
ONCOIMMUNOLOGY (2019)
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
Reem Saleh et al.
VACCINES (2019)
Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial
Sylvia Adams et al.
JAMA ONCOLOGY (2019)
Immunotherapy in triple-negative breast cancer
Heather Katz et al.
MEDICAL ONCOLOGY (2018)
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D. A. Yardley et al.
ANNALS OF ONCOLOGY (2018)
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
Elisa Gobbini et al.
EUROPEAN JOURNAL OF CANCER (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer
Kyung Do Byun et al.
JOURNAL OF BREAST CANCER (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape
Malte Mohme et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies
Carsten Denkert et al.
LANCET (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Emma Nolan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Novel therapeutic strategies in the treatment of triple-negative breast cancer
Karima Oualla et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Lessons from CTLA-4 deficiency and checkpoint inhibition
Bernice Lo et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Novel therapeutic agents in the management of brain metastases
Vyshak A. Venur et al.
CURRENT OPINION IN ONCOLOGY (2017)
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects
Hongyan Jia et al.
DRUG RESISTANCE UPDATES (2017)
Advances in immunotherapy for melanoma
Jason M. Redman et al.
BMC MEDICINE (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
B. Homet Moreno et al.
BRITISH JOURNAL OF CANCER (2015)
Clinical Development of Immune Checkpoint Inhibitors
Ayumu Ito et al.
BIOMED RESEARCH INTERNATIONAL (2015)
TIMgenes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
Gordon J. Freeman et al.
IMMUNOLOGICAL REVIEWS (2015)
Therapeutic use of anti-CTLA-4 antibodies
Christian U. Blank et al.
INTERNATIONAL IMMUNOLOGY (2015)
Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer
Ke Pan et al.
CLINICAL CANCER RESEARCH (2014)
Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
Kent Shih et al.
DRUGS (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.
Shaveta Vinayak et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Clinical Development of the Anti-CTLA-4 Antibody Tremelimumab
Antoni Ribas
SEMINARS IN ONCOLOGY (2010)
Triple-negative breast cancer-current status and future directions
O. Gluz et al.
ANNALS OF ONCOLOGY (2009)
CD28 and CTLA-4 coreceptor expression and signal transduction
Christopher E. Rudd et al.
IMMUNOLOGICAL REVIEWS (2009)
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Marilyn L. Kwan et al.
BREAST CANCER RESEARCH (2009)
Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation
B. B. J. Hermsen et al.
EUROPEAN JOURNAL OF CANCER (2007)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
